Background-Randomized trials show improved outcomes among acute coronary syndrome patients treated with bivalirudin. The objective of this analysis was to compare clinical and economic outcomes in ST-elevation myocardial infarction (STEMI) patients encountered in routine clinical practice undergoing primary percutaneous coronary intervention (PPCI), treated with bivalirudin or heparinϩGP IIb/IIIa receptor inhibitor (heparinϩGPI). Methods and Results-STEMI admissions from January 1, 2004 through March 31, 2008 among patients receiving PPCI and bivalirudin or heparinϩGPI in the Premier hospital database were identified. The probability of receiving bivalirudin was estimated using individual and hospital variables; using propensity scores, each bivalirudin patient was matched to 3 heparinϩGPI treated patients. The primary outcome was in-hospital death. Rates of bleeding, transfusion, length of stay, and in-hospital cost were secondary outcomes. There were 59 917 STEMI PPCIs receiving bivalirudin (nϭ6735) or heparinϩGPI (nϭ53 182). Seventy-nine percent of bivalirudin patients matched, resulting in 21 316 STEMI PPCIs for analysis. Compared with heparinϩGPI patients, bivalirudin patients had fewer deaths (3.2% versus 4.0%; Pϭ0.011) and less inpatient bleeding (clinically apparent bleeding [6.9% versus 10.5%, PϽ0.0001], clinically apparent bleeding with transfusion [1.6% versus 3.0%, PϽ0.0001], and transfusion [5.9% versus 7.6%, PϽ0.0001]). Patients receiving bivalirudin had shorter average length of stay (mean 4.3 versus 4.5 days; PϽ0.0001), with lower in-hospital cost (mean $18 640 versus $19 967 [median $14 462 versus $16 003], PϽ0.0001). Conclusions-This large "real-world" retrospective analysis demonstrates that bivalirudin therapy compared with heparinϩGPI is associated with a lower rate of inpatient death, inpatient bleeding, and decreased overall in-hospital cost in STEMI patients undergoing PPCI. (Circ Cardiovasc Qual Outcomes. 2012;5:52-61.)
H eparin based anticoagulation paired with glycoprotein IIb/IIIa receptor inhibition (GPI) remains the most commonly used medical regimen during primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI), but is limited by the risk of bleeding. Such complications have been associated with reduced survival in follow-up. 1 Bivalirudin, a direct thrombin inhibitor, is indicated for use during percutaneous coronary intervention (PCI), and has been compared with heparinϩGPI across a large spectrum of patient populations, including those undergoing elective and urgent PCI procedures. In the context of randomized trials, bivalirudin has been associated with reductions in the rates of bleeding and in net adverse clinical events, 2-4 compared with heparinϩGPI.
The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial investigated whether antithrombotic therapy with bivalirudin compared with heparinϩGPI could yield improved outcomes at 30 days among STEMI patients undergoing PPCI. 4 Use of bivalirudin was associated with a reduced rate of a composite end point that included death, reinfarction, major bleeding, target-vessel revascularization for ischemia, and stroke at 30 days, compared with heparinϩGPI. Bivalirudin was associated with a significant decrease in overall and cardiac mortality at 30 days. 4 The survival benefit was maintained out to 3 years of follow-up. 5 It is unknown whether the results of randomized trials would be similar in patients encountered in routine practice, where the risk of recurrent ischemic events, bleeding events, and comorbidities are higher compared with randomized clinical trials. As such, confirmation of results from randomized trials with those from large observational databases can inform policy makers when making therapy decisions in the current economically challenged healthcare environment.
A previous analysis from the Premier Perspective database involving a diverse group of elective and urgent PCI patients demonstrated a 33% reduction in rates of blood transfusion and a 49% risk reduction in hospital death, 6 but the in-hospital outcomes and costs associated with bivalirudin use in routine practice among STEMI patients were not examined. This analysis serves to build and expand on those data by focusing on STEMI patients and evaluating not only clinical, but also economic outcomes from the perspective of the United States hospital. We hypothesized that outcomes among STEMI patients receiving bivalirudin during PPCI from an observational cohort would be similar to those seen in the randomized trial, and that improved clinical outcomes would be associated with reduced in-hospital costs. Therefore, a clinical and economic evaluation using the Premier hospital database was performed. The objectives of the study were to compare the rates of in-hospital death, bleeding and transfusion, and length of stay (LOS), as well as in-hospital costs, among STEMI patients receiving either bivalirudin or heparinϩGPI during PPCI.
WHAT IS KNOWN
• In a randomized trial, bivalirudin compared with heparinϩglycoprotein IIb/IIIa inhibition is associated with reduced bleeding complications and improved survival during STEMI treated with primary PCI. • In a registry population of patients undergoing both elective and urgent PCI, bivalirudin was associated with improved outcomes. • Clinical and economic outcomes among STEMI patients outside of clinical trials treated with bivalirudin are unknown.
WHAT THE STUDY ADDS
• Bleeding complications are reduced with bivalirudin compared with heparinϩglycoprotein IIb/IIIa inhibition in a registry population of STEMI patients treated with PCI. • Economic outcomes are improved among STEMI patients treated with PCI and bivalirudin.
Methods
We conducted a 2-group retrospective cohort study using discharges drawn from a large contemporary observational database.
Data Sources
We used the Premier hospital database described previously. [7] [8] [9] Premier is one of the largest United States hospital clinical and economic databases. The data are received from over 600 hospitals, representing all geographical areas of the United States, a broad range of bed sizes, and teaching, nonteaching, urban, and rural facilities. Nearly 5 million inpatient discharges and over 30 million hospital outpatient visits are recorded annually in the Premier database. The database contains standard data elements available in most hospital discharge files, such as demographic data, diagnoses, and procedures performed. In addition, the Premier database also contains patient-level, day-of-service billed items, including procedures, medications, laboratory, and diagnostic and therapeutic services delivered during the hospitalization. Actual costs for goods and services are available for approximately 75% of patients, and 25% of bills were constructed using cost-to-charge ratio estimates for each hospital using standard methods. 10 Premier receives hospital data on a quarterly or monthly basis, and hospitalizations are organized by month and year of admission. The data undergo quality checks, and cost information is reconciled with the hospitals' financial statements. Hospitals use these data to benchmark their clinical and financial performance against their peers.
Patient Population
Primary percutaneous coronary intervention hospitalizations with a claim of the principal diagnosis for STEMI (codes 410.0 to 410.6 and 410.8, in the International Classification of Diseases, 9th Revision [ICD-9]) from January 1, 2004 to March 31, 2008 were selected. No patients were enrolled under the 410.X2 codes. These indicate subsequent episode of care and were unlikely to indicate care for STEMI patients at index presentation. PPCI was defined as the presence of an ICD-9 procedure code or current procedural terminology code for percutaneous transluminal coronary angioplasty, coronary stent, or atherectomy on the day of admission. The PPCI procedure day was determined using patients' billing records or the procedure file. For patients with more than 1 PCI procedure in a given hospitalization, the first procedure day was used in the analysis.
Definition of Treatment Groups
Treatment with anticoagulant was determined from charges in patients' billing record. Patients were categorized into 1 of 2 treatment groups, bivalirudin or heparinϩGPI. Bivalirudin patients were required to have a charge for intravenous bivalirudin without a charge for GPI on the day of the PPCI. Patients categorized as receiving bivalirudin alone may have received treatment with unfractionated heparin (UFH; 15.2%) or low molecular weight heparin (12.8%) before the day of the PPCI. HeparinϩGPI patients were required to have a charge for low molecular weight heparin or UFHϩGPI, without a charge for bivalirudin on the day of the PPCI. A total of 103 446 patients with a principal diagnosis for STEMI were identified. We excluded patients ( Figure) who were less than 18 years of age (nϭ2), patients with unknown gender (nϭ1), patients with unknown or invalid PPCI procedure day (nϭ952), patients with an outpatient PPCI procedure (nϭ274), patients with subsequent or unknown episode of care for STEMI (nϭ658), patients who received fibrinolytic therapy during their admission (nϭ2573), patients without a record of any anticoagulant (nϭ20 821), patients who received bivalirudinϩGPI (nϭ5704), and patients who received heparin alone (nϭ12 544). The resulting study cohort included 59 917 patients from 276 hospitals.
Primary Outcomes
The clinical outcomes included vital status at discharge and occurrence of any bleeding events during the PPCI hospitalization. The bleeding definitions were based on ICD-9 diagnosis codes for bleeding and billing charges for transfusions. Clinically apparent bleeding was defined prospectively as an ICD-9 diagnosis code for bleeding (onlineonly Data Supplement Appendix I). Transfusion was defined as a charge for at least 1 unit of whole blood, packed red blood cells, and fresh frozen plasma or platelets as determined by charges on or after the PPCI procedure day. Clinically apparent bleeding requiring transfusion on or after the PPCI procedure day was defined prospec-tively as the presence of any ICD-9 diagnosis code for bleeding with transfusion of blood products.
Economic outcomes included LOS and in-hospital cost associated with the PPCI hospitalization. LOS was defined as the date of discharge subtracted from the data of admission, plus 1. The total cost per hospital discharge represented the actual cost to treat the patient and includes all supplies, labor, depreciation of equipment, laboratory, medications, and procedures. Cost was adjusted to 2008 United States dollar value using the consumer price index.
Confounders
Patient-level and hospital-level characteristics were identified from the database. Patient socio-demographic factors included age, sex, race/ethnicity, and type of medical insurance. Patient admission details included year of admission, admission type, and hospital transfer status. Patient comorbidities, medical history, and pre-PCI medications (medication use before the PPCI was performed, determined from charges in the patient billing records) also were identified. Hospital characteristics evaluated consisted of hospital teaching status (teaching or nonteaching hospital), geographic region of the hospital (Midwest, Northeast, South, or West), location (urban or rural), and hospital size (number of beds).
Statistical Analysis
Discrete data were reported as frequencies and percentages; continuous data were reported as mean, median, and standard deviation. Comparability between the 2 treatment groups was assessed using standardized differences for each patient and hospital variables before propensity score matching. Standardized differences less than 10% in absolute value support comparability of groups on the basis of the particular variable. 11 Chi-square tests were used to assess differences between treatment groups for discrete variables and Wilcoxon-Mann-Whitney tests for continuous variables.
Because the choice of anticoagulant was not randomized and we observed imbalances in the baseline characteristics between the bivalirudin and heparinϩGPI patients, a propensity score matching strategy was used to reduce the influence of observed imbalances. A logistic regression model was used to estimate the log-odds (logit) of receiving bivalirudin for each patient while controlling for potential patient-and hospital-level confounders. We adopted a Greedy matching algorithm 12 without replacement to match 1 bivalirudin patient to 3 heparinϩGPI patients to increase statistical efficiency. We accepted as matches only those heparinϩGPI patients who were within 0.6 standard deviation of the bivalirudin patient's estimated log-odds of receiving bivalirudin. The 0.6 value was selected as it has been shown to eliminate approximately 90% of the bias in observed confounders. 13 Balance between the 2 treatment groups was assessed using standardized differences for each covariate included in the model using the matched sample. If the percent difference was larger than 10%, we re-estimated the logistic regression model through the inclusion of interaction terms. We repeated this process until all standardized differences were less than 10%.
Conditional logistic regression was performed on the matched sets to estimate the inpatient mortality and bleeding outcomes associated with the 2 anticoagulation strategies. Non-normally distributed data, including cost and LOS, were compared by the stratified signed-rank test.
Sensitivity Analyses
We undertook 2 sensitivity analyses. First, we estimated the degree of residual confounding required to alter the conclusions of the study. In a study with no residual confounding, the odds of 2 patients with identical covariates receiving bivalirudin versus heparinϩGPI is 1; when the treatment odds are greater than 1 after adjusting for observed covariates, bivalirudin patients would be more likely to receive bivalirudin because of differences in an unmeasured characteristic. We determined the value of the treatment odds at which our conclusions regarding a statistically significant effect would change. This was accomplished by calculating bounds on the significance levels of Mantel-Haenszel test statistics for the binary outcomes and on sign-score statistic for LOS and charges. 14 Because it is impossible to identify which particular patients are more likely to receive bivalirudin when assuming unmeasured confounding, a range in the significance levels was calculated.
Second, we repeated the analysis by including in the bivalirudin group bivalirudin patients who received GPI with the assumption that all of these patients had received GPI for bailout indication. Because we did not know the timing of (pre-PCI, during PCI, or post-PCI) and the indication for GPI (elective versus bailout), exclusion of these patients may have systematically excluded sicker bivalirudin patients.
Results

Unadjusted Analyses
The baseline characteristics of the 2 groups in the study cohort differed ( Table 1 ). The bivalirudin patients tended to be older (median age 63 years versus 59 years), with a higher prevalence of comorbidities such as hypertension, diabetes, PVD, chronic kidney disease, prior tobacco use, and anemia ( Table 1) . Bivalirudin patients were more often female and were more commonly treated in urban areas and at teaching 
Propensity Score Analysis
The propensity score model with a c-statistic of 0.75 included 53 variables (online-only Data Supplement Appendix II). Propensity score matching yielded 5329 bivalirudin patients and 15 987 in the heparinϩGPI group for analysis. After matching, the standardized mean differences for patient and hospital baseline characteristics between the 2 treatment groups were all less than 10% (Table 2) , indicating a small magnitude of difference. In the matched cohort, 8.4% received pre-PPCI unfractionated heparin and 6.0% received pre-PPCI low molecular weight heparin. Rates of stenting were no different between the matched cohort (93.8% bivalirudin versus 93.7% heparinϩGPI). The rates of drug-eluting stent usage were not significantly different for the matched groups (standardized mean differenceϭ3.9%).
The outcomes of the analysis are presented in Table 3 . Among the propensity matched population, conditional logistic regression demonstrated that inpatient mortality was lower with bivalirudin compared with heparinϩGPI (odds ratio 0.80 [95% confidence interval (CI) 0.67 to 0.95]). Clinically apparent bleeding (odds ratio 0.63 [95% CI 0.56 to 0.71]), transfusion (odds ratio 0.75 [95% CI 0.66 to 0.86]), and clinically apparent bleeding with transfusion (odds ratio 0.52 [95% CI 0.41, 0.66]) were significantly lower with bivaliru- 
Sensitivity Analyses
Sensitivity analyses indicated that the mortality and LOS differences may be sensitive to small unmeasured confounding (Table 4 ). In particular, biases characterized by odds ratios of 1.1 for in-hospital mortality and LOS could explain the associations between the 2 treatment groups. For bleeding outcomes other than transfusion, a patient would need to be 1.5 times as likely to receive bivalirudin as other patients in the matched sets, even after adjusting for all the observed confounders. Compared with the primary analysis, sensitivity analyses including patients with bivalirudinϩGPI demonstrated that such patients were not at higher clinical risk. The addition of GPI to bivalirudin eliminated the observed difference in mortality (3.1% versus 3.3%; Pϭ0. 26) , and narrowed the difference in all bleeding outcomes such as clinical bleeding with transfusion as well as median in-hospital cost ( Table 5 ).
Discussion
This analysis is the largest evaluation of clinical outcomes, LOS, and costs for STEMI patients receiving bivalirudin during PPCI. This analysis builds on a previous analysis of the Premier Database, 6 where bivalirudin was evaluated in elective and urgently treated PCI patients, some of whom were STEMI patients. This study differs in many important respects. This analysis focuses on economic and clinical outcomes in only STEMI patients treated over a more contemporary time frame, and uses a different study design and inclusion and exclusion criteria, as well as differing statistical methodology. Our findings support the results from numerous randomized clinical trials where bivalirudin has been associated with lower rates of bleeding and the need for transfusion compared with heparinϩGPI. 2, 4 This study extends knowledge regarding improved outcomes associated with bivalirudin to a broader population of STEMI patients treated with PPCI compared with those in randomized trials. As in the HORIZONS-AMI trial evaluating bivalirudin in STEMI, 4, 15 we observed lower bleeding rates and improved survival. These data confirm that the findings from HORIZONS-AMI translate to patients encountered in routine clinical practice and also demonstrate an association of bivalirudin use with inhospital cost savings of approximately $1300/admission when compared with heparinϩGPI. Bleeding rates were lower with bivalirudin in our study compared with the HORIZONS-AMI trial. Our definition of bleeding differs from the clinical definition used in HORIZONS-AMI because hemoglobin values, clinical narratives, and formal adjudication of bleeding events were not available in this administrative dataset. The definition for this study relied on appropriate ICD-9 coding for bleeding and charges for transfusion. Thus, the absolute rates of bleeding in this cohort cannot be compared with those from randomized trials. Nevertheless, the inclusive definition of bleeding used in this analysis was applied uniformly to both the bivalirudin and heparinϩGPI groups, allowing for qualitative conclusions comparing the 2 strategies to be made. In the overall cohort, the rates of repeat revascularization in hospital were similar. Because the indication for repeat revascularization was not captured in this dataset, whether revascularization was performed urgently for recurrent ischemia or as part of a staged procedure is unknown.
As was the case in the previous analysis from the Premier database, 6 bivalirudin patients had more comorbidities and were treated more often at urban teaching hospitals. The reason for clinicians selecting bivalirudin over heparinϩGPI in higher risk patients is unclear. Our propensity score matching strategy was used to reduce the effect of confounding on the choice of medication use and outcomes and in order to create populations with similar observed risk profiles. Furthermore, the matching process afforded the opportunity to reduce the effect of hospital variability on outcomes. The latter is well known to be associated with differences in outcome in STEMI. 16 The mechanism for improved survival associated with bivalirudin monotherapy remains unknown. Because bleeding and transfusion have been associated with adverse events, [17] [18] [19] it is postulated that these are causal rather than noncausal correlates. 20, 21 Our analysis supports the growing body of data linking bleeding events and transfusion with 
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adverse events, but does not provide incremental data as to causality. Nevertheless, sensitivity analyses did show that unmeasured confounding could be responsible as well for the association of bivalirudin and improved survival during PPCI for STEMI. Furthermore, sensitivity analysis showed that exposure to GPI with bivalirudin eliminated the mortality benefit, and narrowed the difference in bleeding outcomes and cost savings. It cannot be ascertained from this analysis whether these differences are causally related to the GPI, bivalirudin, or the combination, or to unmeasured differences in patient risk or management. However, in the context of findings from an acute coronary syndrome population in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, where addition of GPI to bivalirudin did not improve ischemic outcomes, increased rates of bleeding, and costs, 22 one may postulate that the addition of GPI to bivalirudin should be limited to bailout indications. Understanding the clinical and economic consequences related to the use of GPI with bivalirudin during STEMI requires more prospective investigation and is beyond the scope of this analysis.
Limitations
Inherent in most retrospective analyses, residual confounding may affect the association of bivalirudin use and improved outcomes and lower cost, despite use of statistical models. Furthermore, detailed individual patient data such as angiographic characteristics, laboratory values (hemoglobin, cardiac biomarkers, creatinine clearance), indications for repeat PPCI, and rates of recurrent myocardial infarction, urgent revascularization, stent thrombosis, and bailout usage of GPI are not available. This analysis focused on in-hospital outcomes and so the influence of stent type (drug-eluting versus bare metal) on outcomes, which may affect differentially subsequent rates of repeat revascularization and costs, were not included. Details such as timing and duration of medication exposure (eg, pretreatment with clopidogrel and GPI) are not available. A significant number (nϭ20 821) of patients were excluded for missing anticoagulant data. Our focus was on in-hospital outcomes. Because LOS was shorter for bivalirudin patients compared with heparinϩGPI patients, it is possible there are more out-of-hospital events for the bivalirudin patients.
It is important to note that this study did not include an evaluation of patients receiving heparin alone. One may wonder whether bleeding rates would be even lower with heparin alone during PPCI for STEMI, and this may very well be the case; however, numerous studies have demonstrated improved angiographic and ischemic outcomes with addition of GPI, 23, 24 and use of GPI with heparin reflects current practice patterns in the care of STEMI patients. It is possible that the advantage of bivalirudin relates to avoidance of GPI and attendant bleeding complications, but the economic and long-term clinical consequences of any increase in ischemic complications would need to be considered in such an analysis as well.
Furthermore, the ISAR-REACT-3 study evaluated a group of patients undergoing PCI with stable and unstable angina and found higher rates of bleeding with UFH compared with bivalirudin (3.1% versus 4.6% in the unfractionated-heparin group (relative risk 0.66; 95% CI, 0.49 to 0.90; Pϭ0.008). 25 Using the National Cardiovascular Data Registry and estimates of the bleeding reduction noted in ISAR-REACT-3, bivalirudin compared with UFH was estimated to be costeffective for only a minority of patients, such as those with high (Ͼϭ8%) bleeding risk. 26 These findings are evidence to support use of heparinϩGPI as a reference strategy, and potential comparisons of these economic results versus a strategy of heparin monotherapy (which would certainly have a very low drug costs) are speculative at best.
One may hypothesize that more extensive clopidogrel pretreatment or use of more potent oral antiplatelet agents may either improve ischemic outcomes compared with the agents studied here, increase bleeding rates, or both. This analysis evaluated patients before widespread use of prasugrel or ticagrelor, and the timing of administration of clopidogrel is unknown.
Conclusions
Among United States patients undergoing PPCI for management of STEMI, treatment with bivalirudin monotherapy compared with heparinϩGPI resulted in significantly lower rates of inhospital mortality and bleeding. Aggregate hospitalization costs also were lower with bivalirudin. These findings, taken from a less selected population in clinical practice, reinforce outcomes from the HORIZONS-AMI randomized trial and suggest that bivalirudin is an economically and clinically attractive alternative to heparinϩGPI in patients with STEMI. Whether these outcomes can be replicated with newer antiplatelet agents and broader use of bivalirudin in STEMI should be the subject of future investigation.
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